Osteoarthritis Clinical Trials in Los Angeles

View 49 new treatments for Osteoarthritis in Los Angeles, CA. Every day, Power helps hundreds of Osteoarthritis patients connect with leading medical research.

Adipose Allograft for Hand Arthritis

Research Clinic, Los Angeles + 1 more

The purpose the research is to evaluate the safety and efficacy of injection of adipose allograft matrix (AAM) to the small joints of the hand for treatment of early stage osteoarthritis. The hypothesis is that use of AAM injected directly into the joint will show improvements in pain and disability while providing a safe, off-the-shelf alternative which can obviate the need for, and risks associated with, current treatment options with autologous fat transfer. As standard of care, routine strength, pain scale scores (VAS) and range of motion will be recorded, a baseline disability survey (DASH score) will also be administered. After these have all been recorded and administered in a separate visit the patient will undergo the lipofilling procedure. The subject population will include patients over the age of 18 who present with joint pain of the hand with radiographic evidence of osteoarthritis.Show More
Recruiting

No Placebo Trial

Phase < 1
Est. 6 - 12 Weeks
Meghan McCullough, MD
Principal Investigator

Biologic Therapy for Osteoarthritis Prevention After ACL Injury

Research Clinic, Los Angeles + 1 more

Anterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury. Unfortunately, ACL reconstruction does not prevent risk of future OA. Interleukin-1 (IL-1) levels in the human knee joint increase transiently after an ACL injury. In animal experiments, if interleukin-1 levels are increased in the joint, this alone causes arthritis to occur. Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring inhibitor of IL-1. However, in ACL injuries the balance of these two proteins is disturbed transiently after injury, with the effects of IL-1 dominating this balance. In a large animal model of ACL injury, injection of IL-1Ra into the knee joint after ACL injury significantly decreased the amount of arthritis that was later observed. Thus, the investigators hypothesize that early injection of IL-1 inhibitor (IL-1Ra) into the knee joint of patients suffering recent ACL injury will decrease the incidence of cartilage damage later in life. After appropriate IRB approval, a total of 32 active patients will be randomized into one of two treatment groups. Group 1 will receive removal of the knee joint fluid (aspiration of hemarthrosis) using a needle and syringe within 1 to 2 weeks of injury. Following aspiration of the knee joint, an injection of 5 milliliters (mls) of sterile saline (as a placebo control) will be administered. In addition, a second knee aspiration procedure and an injection of 5mls of sterile saline into the injured knee joint will be performed at 3 to 5 days after the initial injection. Group 2 will receive aspiration of the knee hemarthrosis as described in group 1 as well as intra-articular administration of 150mg (\~5mls) of anakinra (rhIL-1Ra) within 1 to 2 weeks of ACL injury. In addition, a second knee aspiration and intra-articular administration of 150mg (\~5mls) of anakinra (rhIL-1Ra) will be performed at 3 to 5 days after the initial injection. Thus, all patients in this randomized placebo-controlled trial will undergo two injection procedures prior to surgery. Investigators will analyze subjects self-reported function and pain scores as well as urinary levels of cartilage breakdown products over time. Additionally, MRI studies will be used to compare MRI findings among patients in these 2 treatment groups. Urine samples will be obtain prior to surgery, at the time of surgery and at multiple time points after surgery (3, 6, 9, 12 and 24 months after surgery). Subjective outcome measure assessments (surveys) will be completed by participants prior to surgery and then again at 6, 9, 12 and 24 months post-operatively. MRI studies will be obtained at 1 year and 2 years following surgery. Additional, MRI studies at time points are optional and highly encouraged. These additional MRIs are at no cost to the patient.Show More
Recruiting
Phase < 1
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Wharton's Jelly Injections for Knee Osteoarthritis

R3 Clinic, Beverly Hills + 1 more

This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.Show More
Recruiting

No Placebo Trial

Phase < 1
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Zolpidem for Spinal Fusion Recovery

Research Clinic, Los Angeles + 1 more

The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.
Recruiting
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Beverly Hills + 7 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
David W Romness, MD
Principal Investigator

Amniotic Suspension Allograft for Knee Osteoarthritis

Organogenesis Clinic, Pomona + 2 more

This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

RTX-GRT7039 Injections for Knee Osteoarthritis

Grünenthal Clinic, Thousand Oaks + 2 more

This trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

RTX-GRT7039 Injection for Osteoarthritis

Grünenthal Clinic, Cerritos + 6 more

This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

TG-C for Osteoarthritis of the Knee

Kolon TissueGene Clinic, Santa Monica + 6 more

This trial tests TG-C, an injection into the knee, for patients with moderate to severe osteoarthritis. It aims to reduce pain and improve knee function by potentially modifying the disease. TG-C has shown promise in previous studies for managing knee osteoarthritis.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Moon Jong Noh, PhD
Study Chair

A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Biosplice Clinic, Pomona + 12 more

This trial tests a knee injection called lorecivivint for people with severe knee osteoarthritis. The injection aims to reduce pain and improve movement by targeting the painful knee directly. Lorecivivint (LOR) is being tested for its potential to treat osteoarthritis.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Yusuf Yazici, M.D.
Study Director
Page 1 of 4

Frequently Asked Questions

How much do osteoarthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do osteoarthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across osteoarthritis trials in Los Angeles, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for osteoarthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.